Solute carrier proteins and the uptake of cytotoxic approved drugs

Información del proyecto

DrugsUP

Identificador del acuerdo de subvención: 661491

DOI

10.3030/661491

Proyecto cerrado

Fecha de la firma de la CE 28 Abril 2015

Fecha de inicio 1 Mayo 2015

Fecha de finalización 30 Abril 2017

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 178 156,80

Aportación de la UE

€ 178 156,80

Coordinado por

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Austria

Periodic Reporting for period 1 - DrugsUP (Solute carrier proteins and the uptake of cytotoxic approved drugs)

Período documentado: 2015-05-01 hasta 2017-04-30

Resumen del contexto y de los objetivos generales del proyecto

The transport of nutrients and metabolites across lipid membranes is a critical and essential biological process in both normal and pathological conditions. Specialized integral membrane proteins known as transporters are responsible for the movement of virtually any known class of biologically active molecules across membranes. Perhaps not surprisingly, there is increasing evidence that many drugs in clinical use also use carried-mediated transport as the predominant entry method into the cell. Understanding the molecular and physiological basis of transporter-mediated drug uptake is therefore a key step toward the development of improved pharmacokinetics and models of toxicity for current and future therapeutically active compounds. We hypothesized that most approved drugs may require specific members of the solute carrier (SLC) family to cross the cell membrane, a phenomenon that would directly affect the compound activity, and that this process is basically underestimated in its importance. To test this hypothesis, the studies performed aimed at identifying SLC transporters involved in the uptake of a well-characterized set of commercialized drugs by a functional genetics screening approach. By screening a large panel of drugs in the HAP1 human cell line with a focused, custom-made CRISPR/Cas9 library, we identify a large number of SLC-drug associations that encompass both known and novel interactions.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Within the project we generated a set of tools to study systematically the largely uncharacterized family of solute carrier (SLCs), comprising most of the human membrane transporters. In particular, we generated a library of CRISPR/Cas9 constructs able to selectively inactivate SLCs genes in human cells, allowing us to screen for genes that are involved in determining the potency of cytotoxic approved drugs (such as for example antitumour drugs). A large set of such compounds (>50) was identified and tested with the library, yielding a number of SLC-drug associations that are now undergoing validation to confirm and understand further their role and mechanism of action. By using different concentration of the compounds, we were able to find correlation between the strength of the hit SLCs and the selective pressure applied, providing an additional layer of validation. Importantly, we identify many known SLC-drug associations (such for example the role of folate transporters in anti-folate drugs uptake or the role of nucleoside transporters in decitabine/cytarabine uptake) therefore confirming the robustness of our approach. The results generated will be disseminated by both presentation at international conferences and by scientific publications, currently in preparation.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The identification of a set of novel drug interactions is an exciting progress in a highly understudied field with the potential to improve the distribution and potency of drugs and improve our understanding of side effects and interaction with other compounds. By knowing how drugs enter cells and how metabolism influences the potency of a drug, it would be possibly to design compounds with improved efficacy (improved metabolism, increased uptake), a better distribution profile (higher uptake, less excretion) and limited side effects (by for example targeting only specific organs based on the pattern of transporters expressed). As these are some of the factors that critically affect the rate at which new compounds are approved for clinical use, we expect that these findings will have large and significant societal and economic implications.

drugsup-graphicalsummary.png